openPR Logo
Press release

Adalimumab Market Thrives as Biosimilars Gain Stronghold in Autoimmune Disease Treatments | AbbVie | Boehringer Ingelheim | Amgen

05-12-2025 05:55 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Adalimumab Market

Adalimumab Market

Adalimumab Market Overview

Adalimumab Market will grow from USD 20.3 billion in 2025 to USD 31.8 billion by 2032, showing a CAGR of 6.6%.

Coherent Market Insights is pleased to release its latest Adalimumab Market research report, offering an in-depth analysis of the U.S. Adalimumab Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional levels, encompassing supply chain shifts, payer-provider dynamics, and competitive intelligence. The U.S. Healthcare Industry continues to advance rapidly, fueled by the rising burden of chronic conditions, growing healthcare expenditure, and innovations in biotechnology and digital health. Our report presents a comprehensive assessment of market forces-from value-based care and patient-centric models to policy and regulatory transformations shaping the future of healthcare delivery.

💡Request Your Sample Copy of the US Tariff Impact Analysis Now: - https://www.coherentmarketresearch.com/samplepages/91209

Driving Strategic and Clinical Excellence

This healthcare-focused report serves stakeholders across the care continuum-including providers, payers, investors, and executives-with actionable market intelligence on the evolving U.S. Health Ecosystem. It provides segmentation by therapeutic specialties, care delivery models, and payer categories. Insights are validated by clinical experts and policy analysts. Methodology includes clinical trial reviews, reimbursement trends, and patient outcome benchmarking-supported with data visualizations, dashboards, and region-specific analysis.

Key therapeutic areas covered include oncology, cardiovascular disease, and rare disorders, along with rising trends such as AI-enabled diagnostics, telehealth adoption, and personalized medicine. This report enables informed decision-making aligned with changing reimbursement models, regulatory standards, and patient expectations in the U.S. Adalimumab Market.

📌 Key Healthcare Companies Profiled:

◘ AbbVie Inc.
◘ Amgen Inc.
◘ Boehringer Ingelheim
◘ Pfizer Inc.
◘ Samsung Bioepis

⏩ Market Segmentation:

Application: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis

Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

📊 Report Scope

This report provides a dual focus on the U.S. and Global Adalimumab Markets, analyzing federal and state policy developments, payer reforms, CMS programs, and FDA regulatory updates. It examines historical benchmarks and forecasts for revenue and patient volumes. Technologies reviewed include EHR systems, medical devices, precision therapeutics, and mobile health (mHealth) platforms.

The report also evaluates equity initiatives, provider shortages, and insurance coverage disparities, offering data-driven strategies for navigating risks and enabling growth across the U.S. healthcare economy.

📌 Research Methodology:

Our research combines primary interviews with healthcare providers, health system executives, and policymakers, with secondary data from CDC, CMS, FDA, and leading peer-reviewed journals. This ensures that the Adalimumab Market analysis remains both clinically accurate and business-relevant.

🗺️ U.S. Regional Market Deep Dive:

Northeast: New York, Massachusetts, Pennsylvania
Midwest: Illinois, Ohio, Michigan
South: Texas, Florida, Georgia
West: California, Washington, Arizona

Each region includes evaluation of health system infrastructure, demographic needs, reimbursement trends, and digital innovation readiness.

✅Get Up to 70% Discount on the US Tariff Impact Analysis Report : https://www.coherentmarketinsights.com/promo/buynow/91209

Read More Trending Articles

Adoptive Cell Therapy Market - https://www.biospace.com/press-releases/adoptive-cell-therapy-market-size-to-hit-23-440-7-million-by-2030-coherent-market-insights#:~:text=According%20to%20Coherent%20Market%20Insights,21.5%25%20from%202023%20to%202030.

Gastroenterology Market - https://www.biospace.com/press-releases/gastroenterology-market-projected-to-reach-usd-53-10-billion-by-2031-says-coherent-market-insights#:~:text=According%20to%20Coherent%20Market%20Insights,6.1%25%20from%202024%20to%202031.

Medical Device Contract Manufacturing Market - https://www.biospace.com/press-releases/medical-device-contract-manufacturing-market-size-to-outpace-us-192-3-billion-by-2030-says-coherent-market-insights-inc#:~:text=Medical%20Device%20Contract%20Manufacturing%20Market,%2D%20BioSpace

Gene Therapy Market - https://www.biospace.com/press-releases/gene-therapy-market-is-estimated-to-witness-high-growth-owing-to-increasing-prevalence-of-genetic-disorders

Chemotherapy Market - https://www.biospace.com/press-releases/chemotherapy-market-size-to-reach-usd-18-35-billion-by-2031#:~:text=According%20to%20the%20latest%20Research,of%207.8%25%20during%20this%20period.

💬 Key Questions Addressed in This Healthcare Report:

(1) Who are the leading healthcare companies in the U.S. market?
(2) What technological and clinical trends will shape healthcare delivery by 2032?
(3) How are providers responding to regulatory shifts from CMS and FDA?
(4) What payer strategies are optimizing outcomes and lowering costs?
(5) Which segments are most influenced by precision medicine and remote monitoring?
(6) How will healthcare policy reforms impact the U.S. economy?
(7) What is the projected growth trajectory for the U.S. healthcare sector?

✍️ Report Author:
Vaagisha is a seasoned healthcare content editor with over three years of experience in medical market analysis. With a life sciences background and a sharp editorial lens, she ensures every report is clinically precise, regulatory-compliant, and strategically aligned for healthcare stakeholders.

About Coherent Market Insights

Coherent Market Insights is a globally trusted Adalimumab Market intelligence and consulting firm offering evidence-based research reports and strategic advisory services. Specializing in pharmaceuticals, medical devices, digital health, and hospital systems, we support health systems, biopharma leaders, policymakers, and medtech innovators with insights tailored for a post-pandemic landscape.

☎️ Contact Us:
Mr. Shah
Senior Client Partner - Business Development
Coherent Market Insights
📞 US: +1-206-701-6702
📞 UK: +44-020-8133-4027
📞 AUS: +61-2-4786-0457
📞 India: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

🌐 Website: www.coherentmarketinsights.com
Follow us: LinkedIn | Twitter

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Adalimumab Market Thrives as Biosimilars Gain Stronghold in Autoimmune Disease Treatments | AbbVie | Boehringer Ingelheim | Amgen here

News-ID: 4011431 • Views:

More Releases from Coherent Market Insights

Probiotic Ingredients Market Growth and Opportunities Insights 2025-2032 | DuPont, Chr. Hansen, ProbioFerm, Synlogic, BioCare Copenhagen
Probiotic Ingredients Market Growth and Opportunities Insights 2025-2032 | DuPon …
The latest study by Coherent Market Insights, titled "Probiotic Ingredients Market Size, Share & Trends Forecast 2025-2032," offers an in-depth analysis of the global and regional dynamics shaping this rapidly evolving industry. This comprehensive report highlights the competitive landscape, key market segments, value chain analysis, and emerging technological and regulatory trends expected between 2025 and 2032. The report provides actionable insights for business leaders, policymakers, investors, and new market entrants
Healthcare IT Consulting Market Booming Worldwide Demand, Growth and Future Scope 2025-2032 | Optum, Cerner Corporation, McKinsey & Company, Deloitte
Healthcare IT Consulting Market Booming Worldwide Demand, Growth and Future Scop …
The qualitative latest Research report (2025-2032) on the Healthcare IT Consulting Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. ➤ Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/139563 Focused on
Organic Soy Protein Market Is Booming So Rapidly 2025 | ADM, DuPont, Cargill, AGT Food and Ingredients, The Scoular Company
Organic Soy Protein Market Is Booming So Rapidly 2025 | ADM, DuPont, Cargill, AG …
The latest study by Coherent Market Insights, titled "Organic Soy Protein Market Size, Share & Trends Forecast 2025-2032," offers an in-depth analysis of the global and regional dynamics shaping this rapidly evolving industry. This comprehensive report highlights the competitive landscape, key market segments, value chain analysis, and emerging technological and regulatory trends expected between 2025 and 2032. The report provides actionable insights for business leaders, policymakers, investors, and new market
Brewing Enzymes Market to Witness Stunning Growth 2025-2032 With Novozymes, DuPont, DSM, AB Enzymes
Brewing Enzymes Market to Witness Stunning Growth 2025-2032 With Novozymes, DuPo …
The latest report titled "Brewing Enzymes Market" Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032. offering a comprehensive and in-depth analysis of the industry. The report provides key insights into current market trends, growth drivers, challenges, and opportunities shaping the market landscape. It also includes a thorough competitor analysis, regional market evaluation, and recent technological or strategic developments influencing the market trajectory. ➤ Currently, the Brewing Enzymes Market holds a strong

All 5 Releases


More Releases for Adalimumab

Adalimumab Biosimilar Market Report and Forecast 2024-2032
Global Adalimumab Biosimilar Market Outlook The adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2024-2032, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population. Adalimumab Biosimilar: Introduction Adalimumab biosimilars are biologic medical products highly similar to the reference product, Humira, which is used to treat autoimmune diseases. These biosimilars offer comparable efficacy, safety, and quality at a
Adalimumab Biosimilar Market Size, Share, Trends 2024-2032
The adalimumab biosimilar market is witnessing substantial growth, driven by the rising incidence of rheumatoid arthritis and an increasing geriatric population. Adalimumab, a popular biologic for treating various inflammatory diseases, has seen a surge in biosimilar counterparts due to their cost-effectiveness and expanding applications. The market is expected to grow at a CAGR of about 17.60% from 2024-2032, reflecting significant opportunities for industry players. Get a Free Sample Report with Table
Adalimumab Market Insights, Forecast to 2031
"Adalimumab Market 2024," The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Adalimumab market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Adalimumab industry, providing stakeholders with a nuanced perspective on market dynamics. Furthermore, the
Adalimumab Market Size, Status & Forecast 2024
Global Adalimumab Market: Overview Adalimumab, with a trade name of Humira and Exemptia, is an anti-TNF drug used for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and ulcerative colitis. Adalimumab usually binds with tumor necrosis factor-alpha (TNFα). When a TNFα binds to a TBFα receptors, it results in an inflammatory response to autoimmune disease. Adalimumab, by binding to a TNFα, lowers the chances of inflammatory response. View Report @ http://www.transparencymarketresearch.com/adalimumab-market.html Adalimumab, which
Adalimumab Market - Forecasts from 2014 to 2020
Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the product are Exemptia and Humira. Humira stands for "human monoclonal antibody in rheumatoid arthritis". Humira targets and acts as building block for TNF-alpha production, and lowering inflammation. TNF blockers with HUMIRA, has adverse affects on the immune system which
Increasing Research and Penetration of Adalimumab Biosimilars Boosts Demand for …
The impending patent expiration has resulted in the sluggish growth rate of the adalimumab market in Latin America. The entry of biosimilars has further aggravated the market’s concerns. Transparency Market Research (TMR) pegs the valuation of the Latin America adalimumab market at US$994.8 mn in 2014. Expanding at a weak CAGR of 0.4% from 2015 to 2023, the market is forecast to reach US$1,186.4 mn by the end of 2023. Download